Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | SMO | Q99835 | 3/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL976548 | 0.91 | PARP10 (0.51) | PARP10DRD4MAPK14SMONPC1 | |
| SCHEMBL977050 | 0.91 | PARP10 (0.51) | PARP10DRD4MAPK14SMONPC1 | |
| SCHEMBL975686 | 0.90 | PARP10 (0.48) | PARP10DRD4MAPK14SMOHPGD | |
| SCHEMBL974841 | 0.90 | PARP10 (0.50) | PARP10DRD4MAPK14SMONPC1 | |
| SCHEMBL978564 | 0.88 | PARP10 (0.50) | PARP10MAPK14SMOSMN1; SMN2HPGD | |
| SCHEMBL977223 | 0.85 | PARP10 (0.51) | PARP10MAPK14SMORAB9ASMN1; SMN2 | |
| SCHEMBL976571 | 0.85 | MAPK14 (0.51) | PARP10MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL976403 | 0.80 | PARP10 (0.60) | PARP10MAPK14SMOSMN1; SMN2HPGD | |
| SCHEMBL2993276 | 0.80 | PARP10 (0.52) | PARP10DRD4MAPK14SMONPC1 | |
| SCHEMBL977938 | 0.79 | PARP10 (0.51) | PARP10MAPK14SMOSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003815-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | MERCK & CO., INC. | 2011-01-06 | — | — | US | disclosed |
| EP-2209761-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | Merck Sharp & Dohme Corp. (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009048547-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | MERCK & CO., INC. (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003815-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | PTGIS, PTGS1, LTC4S | PARP10 567/4885DRD4 2640/4885MAPK14 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.